Project Grant R01CA286111
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$487K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The federal Project Grant award of $581,381 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research by the Sloan-Kettering Institute for Cancer Research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and cancer development, with the goal of...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $445,000.00 to support research on the molecular mechanisms of DNA double-strand break repair by homologous recombination. The award supports the long-term goal of defining the mechanisms of DNA double-strand break repair and contributing to improved treatments for diseases associated with defective DNA repair, such as breast...
This $238,722 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair in the persistence and acquired drug resistance of cancer cells. The key objectives of the 3-year project are to: (1) study persistence in response to PARP inhibitor treatment of BRCA1/2-mutant cancer cells; (2) examine mechanisms of mutagenic DNA repair in...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
This federal Project Grant award for $1,104,864.00, provided by the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program, supports research to understand the molecular mechanisms of homologous recombination and its role in chromosome maintenance and cancer predisposition. The research, conducted by the University of California, Davis, aims to elucidate the functions of key proteins involved in homologous recombination, including BRCA2 and the RAD51 paralogs, and...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $607,250 to the Scripps Research Institute in La Jolla, CA to investigate the role of DNA polymerase theta (POLQ) in repairing replication-associated DNA double-strand breaks and exploiting this as a potential cancer treatment strategy. The award period runs from September 1, 2024 to August 31, 2029. The key objectives of this research project are to...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This $390,000 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to elucidate the mechanisms underlying DNA double-strand break repair. The project, led by researchers at Thomas Jefferson University, aims to provide a better understanding of the complex spatial and temporal organization of key proteins during DNA repair processes and how DNA damage accumulation can...
This $523,292 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to investigate the molecular mechanisms by which the microhomology-mediated end-joining (MMEJ) DNA repair pathway is suppressed in Ewing sarcoma (EWS) cancer cells. The research also aims to assess the function of the MMEJ pathway in EWS patient tumor samples and explore therapeutic approaches that exploit this unique DNA repair...